MPS Powered by Eureka

Current Pharmaceutical Design

ISSN: 1381-6128 (Print)
eISSN: 1873-4286 (Online)

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Special Issues With Active Call for Papers

Submission closes on: Sep 29, 2024
Emerging and re-emerging diseases

Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with several factors, including climate change, evolution of microorganisms and decline in vaccination rates. As if that were not enough, the COVID-19 pandemic itself has also... see more

Submission closes on: Sep 18, 2024
Sensitization of Tumors and Protection of Normal Tissues in Cancer Therapy by Natural and Synthesized Adjuvants

Cancer remains one of the most prevalent and devastating diseases worldwide. The development of effective therapeutic strategies to eradicate tumors while minimizing damage to normal tissues is a major focus of cancer research. In recent years, the field of cancer therapy has witnessed significant advancements in the use of adjuvants, both natural and synthesized, to sensitize tumors and protect normal tissues. Sensitization refers to the process of making cancer cells more susceptible to the action... see more

Submission closes on: Sep 18, 2024
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions

Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and pharmaceutical companies alike. By examining the latest advancements, emerging technologies, and unresolved issues, this issue seeks to foster a deeper understanding of the complexities involved... see more

Submission closes on: Jul 31, 2024
Organic ligands coated metal oxide nanoparticles for biomedical Applications.

Organic Ligands coated metal oxide NPs: Two types of nanoparticles are focused that can be used for biomedical applications for instance, pure and organic ligands coated NPs. The pure NPs preferred for the external organs of the human or animal body. These particles are directly injected inside the tumor through injection. Moreover, the pure nanoparticles are used for the treatment of carcinoma and other biomedical applications. Here it is important to mention that coated nanoparticles... see more

Submission closes on: Jul 30, 2024
"Tuberculosis Prevention, Diagnosis and Drug Discovery"

The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality worldwide with more than 1 million deaths annually. It is also a major contributor to antimicrobial resistance. Thus, early diagnosis and treatment are the most... see more

Submission closes on: Jun 30, 2024
Pharmaceutical Perspectives on Cancer-Targeting Therapy and the Challenges Confronting Drug Response

Targeted therapeutic medications have replaced conventional chemotherapy due to their superior effectiveness and safety. In the years following the 2001 FDA approval of the first tyrosine kinase inhibitor, imatinib, for use in the treatment of cancer, a growing number of small-molecule targeted medicines have been created. 89 small-molecule targeted anticancer medicines will have received approval from the Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China by the end of... see more

Submission closes on: Jun 30, 2024
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances

In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all will be review in this issue. Recent advances on chemotherapy and immunotherapy in the management of melanoma will be reviewed. see more

Submission closes on: Jun 08, 2024
Natural Products and Their Synthetic Scaffolds for Chronic Diseases: A Ray of Hope

Developed over centuries to encode biological processes, nature's products are the dawn and predecessors of medicine. Out of the desire to cure diseases, conventional remedies gave a substantial territory to modern chemical techniques much more competent and capable in the development of new drugs. The designated chemotypes of natural components (β-lactam antibiotics obtained from Penicillium sp. and quinoline/iso-quinoline alkaloids obtained from tree bark are prototypical examples of therapeutically appreciated active substances) have proven their ability... see more

Submission closes on: May 20, 2024
Pharmaceutical Science Strategies for Drug Therapeutic Advancement: Drug Discovery and Development

The process of producing a drug is time-consuming and expensive, but it is also intriguing. The advancement of several computational tools, synthetic methodologies, formulation-based drug discovery, and other techniques has aided in the drug discovery process. The development of new medications is impeded greatly by drug pharmacodynamics and pharmacokinetic issues. Several medicinal approaches/strategies from diverse domains are required to overcome these difficulties. According to this viewpoint, developing effective medications against the target site will necessitate... see more